UK pharmaceutical giant AstraZeneca was downgraded to underweight from neutral on Monday at JP Morgan, which said the company has a strong track record of beating estimates, but this will get tougher in coming quarters as it has to digest generic competition of high-margin products.
AstraZeneca downgraded to underweight at JP Morgan